The Evolution of Incretin Therapy: The Potential Role of GIP/GLP-1 Receptor Agonists in Treating Patients with Obesity and T2DM

FACULTY

Leigh Perreault, MD, FACE, FACP
Associate Professor of Medicine
Division of Endocrinology, Metabolism and Diabetes
Affiliate, Center for Global Health
University of Colorado Anschutz Medical Campus
Associate Professor of Epidemiology and Biostatistics
Colorado School of Public Health

PROGRAM OVERVIEW

This CME program has been designed for endocrinologists who treat patients with type 2 diabetes. It aims to help learners evaluate the impact of weight loss and timely treatment intensification in patients with T2DM on glycemic and metabolic outcomes, and to increase knowledge of the mechanism of emerging GIP/GLP-1 receptor agonists and their impact on glycemic outcomes and body weight in order to advantageously integrate them into clinical practice when available.

LEARNING OBJECTIVES

• Evaluate the impact of weight loss and timely treatment intensification in patients with T2DM on glycemic and metabolic outcomes
• Explain the mechanism of action of GIP/GLP-1 receptor agonists
• Assess the potential role of GIP/GLP-1 receptor agonists in the treatment of patients with T2DM and obesity

TARGET AUDIENCE

This educational activity is intended for endocrinologists who treat patients with T2DM.

ACCREDITATION AND DESIGNATION STATEMENTS

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with type 2 diabetes mellitus.
CNE Credit: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Dr. Perreault has received consulting and/or speaking fees from Novo Nordisk, Sanofi, Boehringer Ingelheim, Elli Lilly and Company, Bayer, Astra Zeneca, WebMD, Medscape, and UpToDate.

CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

• Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
• Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
• Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
• Russie Allen, Outcomes Coordinator for Med Learning Group has nothing to disclose.
• Cindy Lampner, MSLIS, Medical Director, Scientific and Medical Services for Med Learning Group has nothing to disclose.
• Melissa A Johnson, Senior Program Manager for Med Learning Group has nothing to disclose.
• Amanda Jenkins, Associate Program Manager for Med Learning Group has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:

1. Read the CME/CNE information and faculty disclosures.
2. Participate in the enduring activity.
3. Complete and submit the evaluation form to Med Learning Group.

You will receive your certificate after the enduring activity.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.